Carna Biosciences, Inc. announced consolidated earnings results for the first quarter ended March 31, 2020. For the first quarter, the company’s net sales were JPY 335.043 million against JPY 169.964 million a year ago. Operating loss was JPY 165.076 million against JPY 233.119 million a year ago. Ordinary loss was JPY 168.619 million against JPY 233.883 million a year ago. Loss was JPY 184.399 million against JPY 236.814 million a year ago. Basic loss per share was JPY 15.25 against JPY 23.16 a year ago.